Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

GEM-132 enters phase I safety and pharmacokinetic trial

Aug. 23, 1996

SmithKline Beecham describes protease inhibitors

Aug. 23, 1996

Isis now fully owns fomivirsen

Aug. 23, 1996

Solvay to copromote Famvir in U.S.

Aug. 23, 1996

Sequus and Torrex Pharma sign Amphotec marketing agreement

Aug. 23, 1996

Xoma granted permission to commence phase III for rBPI21

Aug. 23, 1996

Parke-Davis and Xenova begin evaluation of novel antibacterial

Aug. 23, 1996

Takeda describes cephem antibacterial agents

Aug. 23, 1996

HHV-8 implicated in KS development

Aug. 16, 1996

Lidak initiates further trials of Lidakol in oral herpes

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...